NCIt definition : A fully human immunoglobulin G1 (IgG1) monoclonal antibody against plasma kallikrein
that can be used for the treatment of hereditary angioedema (HAE). Upon administration,
lanadelumab targets and binds to plasma kallikrein, thereby inhibiting its proteolytic
activity. This inhibits the cleavage of high-molecular-weight-kininogen (HMWK) into
cleaved HMWK (cHMWK) and bradykinin. This in turn may prevent bradykinin-driven vasodilation,
the resulting increase in vascular permeability, and the swelling and pain associated
with HAE. This may also prevent or improve pulmonary edema not associated with HAE
and improve the associated decrease in blood oxygen levels.;